Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase
NCT ID: NCT02216565
Last Updated: 2017-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2014-12-01
2017-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will focus on three particular situations : (1) tandem internal carotid and middle cerebral artery occlusion, (2) situations where patient cannot benefit from fibrinolysis because of high risk of haemorrhage, (3) situations where fibrinolysis is not recommended because of a delay superior to 4.5 hours.
The hypothesis to be tested is that medical approach plus endovascular treatment is superior to medical treatment alone
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical treatment
Conventional medical non-interventional treatment
Hospitalization in specialized neuro-vascular unit
Alteplase if patient is eligible
Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
Supportive care
Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
Endovascular treatment
Conventional medical treatment plus endovascular treatment
Hospitalization in specialized neuro-vascular unit
Alteplase if patient is eligible
Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
Supportive care
Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
Endovascular treatment
Recanalization treatment (thrombectomy / intraarterial thrombolysis)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hospitalization in specialized neuro-vascular unit
Alteplase if patient is eligible
Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
Supportive care
Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
Endovascular treatment
Recanalization treatment (thrombectomy / intraarterial thrombolysis)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
AND one of the three following :
1. tandem internal carotid / middle cerebral artery occlusion
2. intravenous thrombolysis contraindicated because of high risk of haemorrhage
3. intravenous thrombolysis not possible because of delay \> 4.5 hours
Exclusion Criteria
* Clinically minor stroke (NIHSS score below 5 at baseline)
* Extended cerebral infarction
* Severe comorbidity
* Life expectancy below 3 months before stroke
* Pregnancy or breastfeeding
* modified Rankin Score superior to 2 before stroke
18 Years
82 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc-Antoine Labeyrie, MD
Role: PRINCIPAL_INVESTIGATOR
Hopital Lariboisiere, Paris
Michel Piotin, MD
Role: PRINCIPAL_INVESTIGATOR
Fondation Ophtalmologique Adolphe de Rothschild, Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Henri Mondor
Créteil, , France
Fondation Ophtalmologique Adolphe de Rothschild
Paris, , France
Hopital Foch
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A00519-38
Identifier Type: -
Identifier Source: org_study_id